
Knilonat 200mg Tablet
Marketer
Natco Pharma Ltd
Salt Composition
Nilotinib (200mg)
Overview Knilonat 200mg Tablet
Nilotinib 200mg tablets are indicated for treating chronic myeloid leukemia (CML). This medication is prescribed for patients whose leukemia is unresponsive to, or intolerable with, other treatments. For optimal absorption, take Nilotinib 200mg on an empty stomach, consistently at the same time daily. Dosage and frequency are determined by your physician based on your specific condition and may be adjusted. Strictly adhere to your doctor's instructions; improper use or overdose can lead to severe adverse reactions. Therapeutic effects may not be immediately apparent, potentially requiring weeks or months; discontinue only under medical supervision. Common side effects include headache, nausea, stomach pain, and skin rash. Severe diarrhea necessitates medical attention; otherwise, maintain adequate hydration. Nilotinib can lower blood cell counts (red and white blood cells), increasing infection risk. Regular blood tests are essential to monitor blood cell levels, along with heart, liver, and kidney function, uric acid, and lipid profiles. Inform your doctor of any pre-existing heart, liver, or kidney conditions, or concurrent use of anti-infective medications before starting treatment. Drug interactions are possible; disclose all medications to your healthcare provider. This medicine is contraindicated during pregnancy and breastfeeding. Reliable contraception is crucial for both partners throughout treatment to prevent conception.
Primary Ingredients of Knilonat 200mg Tablet
The provided text is "undefined," offering no content to rephrase.
Uses of Knilonat 200mg Tablet
Chronic myeloid leukemia, a type of blood cancer
Major Benefits of Knilonat 200mg Tablet:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the 200mg Knilonat tablet whole; avoid crushing, chewing, or breaking it. Administer on an empty stomach.
Common Side effects of Knilonat 200mg Tablet:
- Headache
- Nausea
- Abdominal pain
- Rash
- Itching
- Hair loss
- Muscle pain
- Fatigue
How to use Knilonat 200mg Tablet:
Consume this medication precisely as prescribed by your physician, adhering to the specified dosage and treatment period. Ingest the 200mg Knilonat tablet whole; avoid chewing, crushing, or fracturing it. Administer on an empty stomach.
How Knilonat 200mg Tablet works:
Oncasin 200mg tablets are a cancer treatment that inhibits the activity of a faulty protein responsible for triggering uncontrolled cancer cell growth, thus hindering or retarding cancer progression.
SAFETY ADVICE
AlcoholSAFE
Ingesting alcohol alongside a 200mg Knilonat tablet presents no known adverse reactions.
PregnancyCONSULT YOUR DOCTOR
Using Knilonat 200mg tablets during pregnancy poses a confirmed risk to the fetus. A physician might exceptionally prescribe it in life-threatening emergencies where potential benefits outweigh the known hazards. Always seek medical advice.
Breast feedingUNSAFE
Administration of Knilonat 200mg tablets is contraindicated while breastfeeding due to potential infant toxicity.
DrivingUNSAFE
Taking a Knilonat 200mg tablet might reduce attentiveness, impair vision, or cause drowsiness and dizziness. Driving is inadvisable if these effects are experienced.
KidneySAFE IF PRESCRIBED
The use of Knilonat 200mg Tablets in patients with kidney impairment appears to pose minimal risk. Existing evidence indicates dose modification may be unnecessary; however, medical advice is recommended.
LiverCAUTION
Individuals with hepatic impairment should exercise prudence when using Knilonat 200mg tablets. Dosage modification of Knilonat 200mg tablets may be necessary. Physician consultation is advised.
What if you forget to take Knilonat 200mg Tablet :
Omit any missed Knilonat 200mg Tablet dose and resume your regular medication regimen. Avoid taking a double dose.
Facts to Know About Knilonat 200mg Tablet
| Label | Value |
|---|---|
| Chemical Type | Aminopyrimidine-based compound |
| Developing Habits | No. |
| Treatment Category | Cancer Drugs |
| Actions | Kinase inhibitors targeting tyrosine |
